BFA
IMUC

BlackRock Fund Advisors’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

BlackRock Fund Advisors’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$1K Buy
672
+97
+17% +$308 ﹤0.01% 4236
2016
Q3 		$3K Buy
575
+60
+12% +$386 ﹤0.01% 4160
2016
Q2 		$5K Buy
515
+39
+8% +$401 ﹤0.01% 4111
2016
Q1 		$6K Buy
476
+92
+24% +$1.03K ﹤0.01% 4079
2015
Q4 		$5K Buy
+384
New +$6.35K ﹤0.01% 4162
2015
Q2 		– Sell
-5,753
Closed -$112K – 4004
2015
Q1 		$112K Buy
5,753
+1,405
+32% +$35.3K ﹤0.01% 3601
2014
Q4 		$127K Buy
4,348
+310
+8% +$8.92K ﹤0.01% 3582
2014
Q3 		$144K Sell
4,038
-293
-7% -$11.3K ﹤0.01% 3575
2014
Q2 		$194K Buy
4,331
+124
+3% +$5.98K ﹤0.01% 3501
2014
Q1 		$205K Buy
4,207
+510
+14% +$24.9K ﹤0.01% 3458
2013
Q4 		$137K Buy
3,697
+155
+4% +$14.7K ﹤0.01% 3526
2013
Q3 		$364K Buy
3,542
+105
+3% +$11.5K ﹤0.01% 3238
2013
Q2 		$267K Buy
+3,437
New +$329K ﹤0.01% 3239

Other funds holding IMUC

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IP
Intellectus Partners San Francisco, California $578M AUM 49.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BlackRock Fund Advisors's IMUC Position: Q4 2016 in Review

BlackRock Fund Advisors increased its ImmunoCellular Therapeutics, Ltd. (IMUC) stake by 17% in Q4 2016, buying an estimated $308 and bringing the position to 672 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #4236.

BlackRock Fund Advisors first reported a position in IMUC in Q2 2013 and has held it in 13 quarters since. The position peaked at $364K in Q3 2013. 16 funds tracked by Wall St. Rank hold IMUC as of Q4 2016.

  • BlackRock Fund Advisors held 672 shares of ImmunoCellular Therapeutics, Ltd. worth $1K as of Q4 2016.
  • BlackRock Fund Advisors bought 97 ImmunoCellular Therapeutics, Ltd. shares in Q4 2016, an estimated $308.
  • ImmunoCellular Therapeutics, Ltd. made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #4236 holding.
  • BlackRock Fund Advisors first reported a position in ImmunoCellular Therapeutics, Ltd. in Q2 2013 and has held it in 13 quarters since.
  • BlackRock Fund Advisors's ImmunoCellular Therapeutics, Ltd. position peaked at $364K in Q3 2013.
  • 16 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.